PAUL WILKEN: Open Payments
NPI 1427579374 · ELKHORN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$285 in 14 payments from 7 companies in 2025. Trend: 2023 $362 · 2024 $153 · 2025 $285
Food & beverage: $285
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $97 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: VRAYLAR, HETLIOZ, CAPLYTA, FANAPT, Auvelity, ARISTADA, COBENFY, Qelbree.
Industry payments across NE — which companies pay providers there.
